1Ellen M, Smith L, et al. The total neuropathy score: a tool for measuring chemo-therapy induced peripheral neuropathy. Oncol Nurs Forum, 2008, 35 ( 1 ) : 96-102.
2Troy L, McFarland K, Littman-Power S, et al. Cisplatin- based therapy: A neurological and neuropsychological review. Psychooncology, 2000, 9( 1 ): 29-39.
3WIIson RH, Lehky T, Thomas RR, et al. Acute oxaliplatin Induced Peripheral Nerve Hyperexcitability. Clin Oncol, 2002, 20(7) : 1767-1774.
5Postma TJ, Aaronson NK, Heimans JJ, el al. The development of an EORTC quality of life questionnaire to assess chemotherapy- induced peripheral neuropathy : The QLQ- CIPNN20. Eur J Cancer, 2005, 41 : 1135-1139.
6Wampler MA, Miaskowski C, Hamel K, et al. The Modified Total Neuropathy Score: a clinically feasible and valid measure of taxane-induced peripheral neuropathy in women with breast cancer. J Support Oncol, 2006, 4(8) : XXX-XXX.
7Chaudhry V, Rowinsky EK, et al. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiologieal studies. Ann Neural, 1994, 35 (3) : 304-311.
8Cavaletti G, Bogliun G, Marzorati L, etal. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann Oncol, 2004, 15: 1439-1442.
9England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: A definition for clinical research: Report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology, 2005. 64(2), 199-207.
10Hamers FP, Van der Hoop RG, Sterenburg PA, et al. Putative neurotrophic factors in the protection of cisplatin-induced peripheral neuropathy in rats. Toxicol Appl Pharmacol, 1991, 111(3): 514-522.
